Lineage plasticity and histologic transformation to small cell neuroendocrine prostate cancer
(NEPC) is an increasingly recognized mechanism of treatment resistance in advanced …

SCLC is an aggressive form of lung cancer with a very poor prognosis. Although SCLC
initially responds very well to platinum-based chemotherapy, it eventually recurs and at …

Abstract Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective,
first-in-class inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR). We …

Purpose: This study reports the safety, tolerability, MTD, recommended phase II dose
(RP2D), pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of …

Abstract Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective,
first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor …

Simple Summary Chemotherapeutic DNA-damaging agents targeting replication are widely
used but predictive rationales for drug combinations and patient selection still need clinical …

Replication stress (RS) is a hallmark of cancer cells that is associated with increased
genomic instability. RS occurs when replication forks encounter obstacles along the DNA …

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy with high
and rapid relapse rates and poor outcomes. Treatment for SCLC has historically been …

Small-cell lung cancer (SCLC) is initially sensitive to platinum doublet chemotherapy,
providing dramatic clinical benefit. Unfortunately, most SCLCs relapse and become resistant …

Mutations of calreticulin (CALR) are the second most prevalent driver mutations in essential
thrombocythemia and primary myelofibrosis. To identify potential targeted therapies for …